Quinazolinone Derivative Selective PI3K Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors for treating solid tumors lack selectivity, often inhibiting multiple isoforms, including p110α, which can lead to off-target effects due to their non-selective nature, and existing treatments for solid tumors rely primarily on p110α inhibition, neglecting the potential therapeutic benefits of targeting p110β and p110δ.
Innovation Solution
A specific optically active quinazolinone compound, predominantly the S-isomer, is developed to selectively inhibit p110β and p110δ, offering higher oral bioavailability and reduced activity against p110α, thereby providing a targeted approach for treating solid tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PI3K inhibitors are used to treat solid tumors, then broad inhibition of multiple PI3K isoforms is achieved, but off-target effects occur due to inhibition of p110α which regulates glucose and insulin levels
Solution Approach 1:
The patent applies local quality by designing a quinazolinone derivative with specific structural modifications (particularly at the 6-position substituent) that confer selective inhibition of p110β and p110δ isoforms while sparing p110α. This localized molecular design enables the drug to target specific pathological isoforms without affecting the physiological p110α pathway, thereby achieving therapeutic efficacy without off-target effects on glucose and insulin regulation
Solution Approach 2:
The patent segments the PI3K inhibition activity by creating isoform-selective inhibitors that target specific p110 isoforms (β and δ) rather than all isoforms uniformly. This segmentation is achieved through rational drug design that exploits subtle differences in the binding pockets of different p110 isoforms, allowing selective blockade of oncogenic isoforms while preserving normal physiological isoforms
2Adaptability or versatility
If p110α-focused inhibitors are used for solid tumor treatment, then existing therapeutic approaches are maintained, but potential therapeutic benefits of targeting p110β and p110δ are neglected
Solution Approach 1:
The patent applies parameter changes by modifying molecular parameters of the quinazolinone core structure, particularly the substituent at the 6-position, to tune the selectivity profile and potency against different p110 isoforms. By varying these molecular parameters, the patent achieves optimal inhibition of p110β and p110δ while maintaining selectivity, thereby expanding therapeutic coverage without excessive complexity
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula I, (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.